Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.42 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.42 |
| ▸ | GPR3 | P46089 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | CRHBP | P24387 | 1/20 | 0.38 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2013304 | 0.75 | CYP2A6 (0.50) | CYP2A6MAPTHDAC3HDAC4HDAC1 | |
| SCHEMBL4381193 | 0.74 | CYP2A6 (0.54) | CYP2A6MAPTHDAC3HDAC4HDAC1 | |
| SCHEMBL11320385 | 0.73 | MAPT (0.52) | CYP2A6MAPTHDAC3HDAC4HDAC1 | |
| SCHEMBL25399747 | 0.73 | LIMK1 (0.38) | MAPTSMN1; SMN2NPC1RAB9AKDM4E | |
| SCHEMBL264791 | 0.72 | CYP2A6 (0.52) | CYP2A6MAPTHDAC3HDAC4HDAC1 | |
| SCHEMBL1308770 | 0.70 | CYP2A6 (0.54) | CYP2A6MAPTHDAC3HDAC4HDAC1 | |
| SCHEMBL6716668 | 0.70 | CYP2A6 (0.50) | CYP2A6MAPTHDAC3HDAC4HDAC1 | |
| SCHEMBL15482286 | 0.70 | CYP2A6 (0.50) | CYP2A6MAPTHDAC3HDAC4HDAC1 | |
| SCHEMBL546825 | 0.70 | CYP2A6 (0.50) | CYP2A6MAPTHDAC3HDAC4HDAC1 | |
| SCHEMBL188594 | 0.70 | CYP2A6 (0.50) | CYP2A6MAPTHDAC3HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119932584-A | Method for synthesizing 1, 1-diaryl compound by using non-activated olefin | 哈尔滨工业大学(深圳)(哈尔滨工业大学深圳科技创新研究院) | 2025-05-06 | — | — | CN | claimed |
| CN-119932584-A | Method for synthesizing 1, 1-diaryl compound by using non-activated olefin | 哈尔滨工业大学(深圳)(哈尔滨工业大学深圳科技创新研究院) | 2025-05-06 | — | — | CN | disclosed |
| CN-116082296-B | Method for preparing 3-halogenated benzothiophene compound by monopersulfate catalysis method | 浙江医药股份有限公司新昌制药厂 | 2024-10-29 | — | — | CN | disclosed |
| CN-118290284-A | Synthesis method and application of alpha-carbonyl amide compound | 遵义医科大学 | 2024-07-05 | — | — | CN | disclosed |
| WO-2024026128-A2 | TRICYCLIC ARYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | ENSEM THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| WO-2023239846-A1 | HETEROCYCLIC COMPOUNDS AS PI3KΑ INHIBITORS | SYNNOVATION THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| EP-4279493-A1 | NOVEL COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | Lg Chem, Ltd. (KR) | 2023-11-22 | — | — | EP | disclosed |
| CN-116082296-A | Method for preparing 3-halogenated benzothiophene compound by potassium monopersulfate catalysis method | 浙江医药股份有限公司新昌制药厂 | 2023-05-09 | — | — | CN | disclosed |
| WO-2023275333-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2023-01-05 | — | — | WO | disclosed |
| WO-2023275337-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2023-01-05 | — | — | WO | disclosed |
| US-20050250959-A1 | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-11-10 | — | — | US | disclosed |
| CN-1684944-A | method for copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds | MASSACHUSETTS INST TECHNOLOGY (US) | 2005-10-19 | — | — | CN | disclosed |
| EP-1534671-A2 | COPPER-CATALYZED FORMATION OF CARBON-HETEROATOM AND CARBON-CARBON BONDS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2005-06-01 | — | — | EP | disclosed |
| US-6888032-B2 | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2005-05-03 | — | — | US | disclosed |
| US-20040138468-A1 | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-07-15 | — | — | US | disclosed |
| WO-2004013094-A2 | COPPER-CATALYZED FORMATION OF CARBON-HETEROATOM AND CARBON-CARBON BONDS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2004-02-12 | — | — | WO | disclosed |
| EP-1115286-A4 | METHODS FOR TREATING OR PREVENTING VIRAL INFECTIONS AND ASSOCIATED DISEASES | VIROPHARMA INC (US) | 2003-07-23 | — | — | EP | disclosed |
| US-6316492-B1 | THERAPY OF INFECTION ONE VIRUS OF THE FLAVIVIRIDAE FAMILY AND DISEASE ASSOCIATED WITH SAID INFECTION BY ADMINISTERING ANTIVIRAL COMPOUND | VIROPHARMA INCORPORATED | 2001-11-13 | — | — | US | disclosed |
| EP-1115286-A1 | METHODS FOR TREATING OR PREVENTING VIRAL INFECTIONS AND ASSOCIATED DISEASES | Viropharma Incorporated (US) | 2001-07-18 | — | — | EP | disclosed |
| WO-2000018231-A1 | METHODS FOR TREATING OR PREVENTING VIRAL INFECTIONS AND ASSOCIATED DISEASES | VIROPHARMA INCORPORATED (US) | 2000-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250959-A1 | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds | CBR3, TST, CBS | CYP2A6 106/4885MAPT 3914/4885HDAC3 1518/4885 |
| US-20040138468-A1 | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds | CBR3, TST, CBS | CYP2A6 102/4885MAPT 3934/4885HDAC3 1566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.